Articoli correlati
Carcinoma polmonare a piccole cellule
Aggressive lung cancer with low five-year survival, focus of the DeLLphi-305 trial combining tarlatamab and durvalumab.
Articoli correlati
Aggressive lung cancer with low five-year survival, focus of the DeLLphi-305 trial combining tarlatamab and durvalumab.